Ocrevus Zunovo (ocrelizumab/ hyaluronidase-ocsq)

Adult Dosing .

Dosage forms:  INJ: 920 mg/23,000 units per 23 mL

Special Note

[drug name clarification]

Info: nonproprietary name = ocrelizumab/hyaluronidase-ocsq

multiple sclerosis, relapsing forms

[920 mg/23,000 units SC q6mo]

Info: for patients with clinically isolated syndrome, relapsing-remitting disease, or active secondary progressive disease; premed with corticosteroid and antihistamine at least 30min before each dose; consider premed with antipyretic

multiple sclerosis, primary progressive

[920 mg/23,000 units SC q6mo]

Info: premed with corticosteroid and antihistamine at least 30min before each dose; consider premed with antipyretic

renal dosing

[see below]

mild impairment: no adjustment; moderate-severe impairment: not defined

HD/PD: not defined

hepatic dosing

[see below]

mild impairment: no adjustment; moderate-severe impairment: not defined

Peds Dosing .

Peds dosing is currently unavailable or not applicable for this drug.